251 related articles for article (PubMed ID: 30728015)
1. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies.
Lin YL; Tsai NM; Chen CH; Liu YK; Lee CJ; Chan YL; Wang YS; Chang YC; Lin CH; Huang TH; Wang CC; Chi KH; Liao KW
J Nanobiotechnology; 2019 Feb; 17(1):25. PubMed ID: 30728015
[TBL] [Abstract][Full Text] [Related]
2. A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells.
Lin YL; Liu YK; Tsai NM; Hsieh JH; Chen CH; Lin CM; Liao KW
Nanomedicine; 2012 Apr; 8(3):318-27. PubMed ID: 21704596
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex.
Lin YL; Chen CH; Wu HY; Tsai NM; Jian TY; Chang YC; Lin CH; Wu CH; Hsu FT; Leung TK; Liao KW
J Nanobiotechnology; 2016 Feb; 14():11. PubMed ID: 26892504
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of cytotoxicity and induction of apoptosis by cationic nano-liposome formulation of
Huang XF; Chang KF; Lin YL; Liao KW; Hsiao CY; Sheu GT; Tsai NM
Int J Med Sci; 2021; 18(13):2930-2942. PubMed ID: 34220320
[TBL] [Abstract][Full Text] [Related]
5. Antibody-conjugated pH-sensitive liposomes for HER-2 positive breast cancer: development, characterization,
Raikwar S; Yadav V; Jain S; Jain SK
J Liposome Res; 2024 Jun; 34(2):239-263. PubMed ID: 37594466
[TBL] [Abstract][Full Text] [Related]
6. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
[TBL] [Abstract][Full Text] [Related]
7. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells.
Yu K; Zhao J; Zhang Z; Gao Y; Zhou Y; Teng L; Li Y
Int J Pharm; 2016 Jan; 497(1-2):78-87. PubMed ID: 26617314
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab-polyethylenimine-polyethylene glycol conjugates for targeting Her2-expressing tumors.
Germershaus O; Merdan T; Bakowsky U; Behe M; Kissel T
Bioconjug Chem; 2006; 17(5):1190-9. PubMed ID: 16984128
[TBL] [Abstract][Full Text] [Related]
9. Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery.
Chen X; Wang M; Yang X; Wang Y; Yu L; Sun J; Ding J
Theranostics; 2019; 9(21):6080-6098. PubMed ID: 31534538
[TBL] [Abstract][Full Text] [Related]
10. Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme.
Lin YL; Chang KF; Huang XF; Hung CL; Chen SC; Chao WR; Liao KW; Tsai NM
Int J Nanomedicine; 2015; 10():6009-20. PubMed ID: 26451107
[TBL] [Abstract][Full Text] [Related]
11. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles.
Lee AL; Wang Y; Cheng HY; Pervaiz S; Yang YY
Biomaterials; 2009 Feb; 30(5):919-27. PubMed ID: 19042015
[TBL] [Abstract][Full Text] [Related]
12. Antitumor Effect of
Gao HW; Chang KF; Huang XF; Lin YL; Weng JC; Liao KW; Tsai NM
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563276
[TBL] [Abstract][Full Text] [Related]
13. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
14. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cells.
Lee YH; Ma YT
J Nanobiotechnology; 2017 May; 15(1):41. PubMed ID: 28521752
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment.
Cui T; Zhang S; Sun H
Oncol Rep; 2017 Feb; 37(2):1253-1260. PubMed ID: 28075466
[TBL] [Abstract][Full Text] [Related]
17. Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy.
Lin M; Teng L; Wang Y; Zhang J; Sun X
Drug Deliv; 2016 May; 23(4):1420-5. PubMed ID: 26203688
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
19. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
20. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
